Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

Clinical Trial ID NCT00243529

Rank	Title	Journal	Year	PubWeight™‹?›
1	Dendritic cell immunotherapy: mapping the way.	Nat Med	2004	4.28
2	Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.	Cancer Res	2003	2.32
3	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.	J Clin Invest	2011	1.91
4	Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.	Clin Cancer Res	2003	1.57
5	Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.	J Clin Oncol	2005	1.48
6	Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.	Proc Natl Acad Sci U S A	2011	1.19
7	Phenotypical and functional characterization of clinical grade dendritic cells.	J Immunother	2002	1.12
8	Migration of dendritic cell based cancer vaccines: in vivo veritas?	Curr Opin Immunol	2005	1.11
9	Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results.	Ann Oncol	2004	0.96
10	Antigen-specific vaccines for cancer treatment.	Hum Vaccin Immunother	2014	0.89
11	New clinical advances in immunotherapy for the treatment of solid tumours.	Immunology	2015	0.76